Nanoparticle-based host-directed therapies for eradication of Mycobacterium tuberculosis

基于纳米颗粒的宿主定向疗法根除结核分枝杆菌

基本信息

批准号：
10376853
负责人：
Admire Dube
金额：
$ 32.82万
依托单位：
STELLENBOSCH UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-04-06 至 2025-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10376853
关键词：
Address Adherence Advanced Development Alveolar Macrophages Animal Model Antibacterial Response Antibiotics Antimicrobial Effect Appearance Architecture Artificial nanoparticles Award Bacteria Bacterial Infections Biocompatible Materials Biomimetics Bone Marrow Buffaloes Case Study Cause of Death Cells Cessation of life Clinical Communicable Diseases Country Data Defense Mechanisms Development Disadvantaged Disease Drug Tolerance Drug resistance Drug resistant Mycobacteria Tuberculosis Exhibits Fluorescence Formulation Funding Goals HIV Health Human Hybrids Immune Immune response Immunity Immunologics Immunology Immunotherapeutic agent Immunotherapy In Vitro Incidence Infection Institution Invaded Kinetics Knowledge Lipids Macrophage Activation Mediating Metals Methods Modeling Molecular Multidrug-Resistant Tuberculosis Mus Mycobacterium tuberculosis Mycobacterium tuberculosis H37Rv Mycolic Acid Nanotechnology Outcome Pathway interactions Persons Pharmaceutical Preparations Pharmacotherapy Phenotype Polymers Polysaccharides Population Positioning Attribute Property Public Health Publishing Regimen Reporter Research Research Personnel Research Project Grants Research Training Rod Scientist Shapes Signal Transduction South Africa South Dakota Standardization Structure System Training Programs Treatment Failure Treatment Protocols Tuberculosis United States United States National Institutes of Health Universities Virulent Work Zimbabwe antimicrobial base beta-Glucans co-infection drug-sensitive immunoregulation improved in vivo innovation latent infection macrophage mimicry multidisciplinary mycobacterial nanomedicine nanoparticle novel pathogen persistent bacteria polycaprolactone resistant strain response tool trafficking tuberculosis treatment uptake

项目摘要

SUMMARY Tuberculosis remains a major global public health threat. Although relatively effective drug regimens are available, treatment failure remains a major roadblock to tuberculosis control. This is in part due to a high incidence of drug-resistant Mycobacterium tuberculosis (Mtb) strains, as well as the phenomenon of bacterial persistence. Persisters represent a reservoir of latent infection, which may progress to active disease when host immunity is compromised (e.g., with HIV co-infection), and also potentially contribute to the emergence of further drug resistance. Mtb is able to subvert key innate immune defence mechanisms exerted by the host macrophage; it can dampen the immune response, subvert macrophage killing and create a protected niche within this host cell. In the proposed work, the capacity of engineered nanoparticles to favourably modulate the response of macrophage, through delivered immunomodulatory signals, and achieve death of intracellular Mtb, will be investigated. These unique nanoparticles mimic Mtb (i.e. bacteriomimetic) in selected aspects of size, shape and composition. The nanoparticles proposed here are lipid polymer hybrid nanoparticles and metal organic frameworks (spherical and rod shaped) incorporating mycolic acids and/or the fungal wall polysaccharide β- glucan. Strong published and preliminary data demonstrates the capacity of the polymer nanoparticles to induce killing of virulent Mtb in macrophages. This killing is only evident in intracellular Mtb and is similar to that achieved using an antibiotic. Metal organic framework nanoparticles can be synthesized and coated with macrophage targeting materials. The hypothesis of the project is that bacteriomimetic, immunotherapeutic nanoparticles will be effective against all forms of Mtb (including drug-resistant and persister populations) through immune modulation. Specifically, the project has 3 aims: 1) Characterize a panel of bacteriomimetic immunotherapeutic NPs; 2) Investigate response of infected macrophages and intracellular bacteria to the panel of NPs; 3) Assess in vivo response to, and efficacy of, NPs in murine infection model. This project is at the cutting edge of nanotechnology and tuberculosis research, and will provide several exciting research capacity development opportunities for scientists from South Africa and Zimbabwe (through a partnership with an on-going NIH funded HIV Research Training Program). The multi-national research team will be led by 3 new investigators, with research teams from Stellenbosch University, South Africa, the University of the Western Cape (a historically disadvantaged institution in South Africa) and South Dakota State University in the USA, partnered to propose a novel immunotherapy approach for tuberculosis based on nanoparticle-based delivery systems. The team has expertise in nanoparticle formulation and characterisation, in vitro and in vivo infection models, and tuberculosis immunology. Our results will advance the development of nanoparticle-based, host-directed therapies for tuberculosis.

概括尽管有相对有效的药物治疗方案，但结核病仍然是全球主要的公共卫生威胁。尽管治疗失败仍然是结核病控制的主要障碍，部分原因是结核病感染率高。耐药结核分枝杆菌 (Mtb) 菌株的发生率以及细菌现象持续存在代表潜伏感染的储存库，当宿主感染时可能会发展为活动性疾病。免疫力受到损害（例如，艾滋病毒合并感染），也可能导致进一步出现 Mtb 能够破坏宿主巨噬细胞发挥的关键先天免疫防御机制；它可以抑制免疫反应，破坏巨噬细胞的杀伤作用，并在宿主体内创造一个受保护的生态位在拟议的工作中，工程纳米颗粒有能力调节细胞的反应。巨噬细胞通过传递免疫调节信号，实现细胞内Mtb的死亡，研究人员对这些独特的纳米颗粒在尺寸、形状和形状的选定方面模仿 Mtb（即拟菌）进行了研究。这里提出的纳米颗粒是脂质聚合物杂化纳米颗粒和金属有机颗粒。结合分枝菌酸和/或真菌壁多糖β-的框架（球形和杆形）已发表的强有力的初步数据证明了聚合物纳米颗粒的诱导能力。杀死巨噬细胞中的有毒 Mtb，这种杀死作用仅在细胞内 Mtb 中明显，并且与所实现的效果相似。使用抗生素可以合成金属有机框架纳米颗粒并用巨噬细胞包被。该项目的假设是仿菌免疫治疗纳米颗粒将通过免疫有效对抗所有形式的 Mtb（包括耐药性和持续性人群）具体来说，该项目有 3 个目标：1）表征一组拟菌免疫治疗药物。 NP；2) 研究受感染的巨噬细胞和细胞内细菌对 NP 组的反应；3) 评估纳米颗粒在小鼠感染模型中的体内反应和功效该项目处于研究的前沿。纳米技术和结核病研究，并将提供一些令人兴奋的研究能力发展为来自南非和津巴布韦的科学家提供机会（通过与正在进行的 NIH 资助的项目合作） HIV 研究培训计划）。多国研究小组将由 3 名新研究人员领导，其中包括：来自南非斯泰伦博斯大学、西开普大学（历史悠久的大学）的研究团队南非的弱势机构）和美国南达科他州立大学合作提出了一项该团队已经开发出了基于纳米颗粒的输送系统的新型结核病免疫治疗方法。纳米颗粒配方和表征、体外和体内感染模型以及结核病方面的专业知识我们的研究结果将推动基于纳米颗粒的、针对宿主的疗法的开发。结核。